Last reviewed · How we verify
Bosentan Dispersible Tablets
At a glance
| Generic name | Bosentan Dispersible Tablets |
|---|---|
| Sponsor | Humanis Saglık Anonim Sirketi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- UPPER RESPIRATORY TRACT INFECTION
- NASOPHARYNGITIS
- PYREXIA
- COUGH
- DIARRHOEA
- VOMITING
- BRONCHITIS
- PULMONARY ARTERIAL HYPERTENSION
- CONSTIPATION
- EPISTAXIS
- VIRAL UPPER RESPIRATORY TRACT INFECTION
- FLUSHING
Key clinical trials
- FUTURE 3 Study Extension (PHASE3)
- Bosentan in Children With Pulmonary Arterial Hypertension Extension Study (PHASE3)
- Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension (PHASE3)
- Bosentan in Children With Pulmonary Arterial Hypertension (PHASE3)
- Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bosentan Dispersible Tablets CI brief — competitive landscape report
- Bosentan Dispersible Tablets updates RSS · CI watch RSS
- Humanis Saglık Anonim Sirketi portfolio CI